Celgene

Exscientia, the Oxford-based pioneer in artificial intelligence (AI)-based drug development, has advanced the first of three candidates planned for first-in-human studies this year—an immunology and inflammation (I&I) small molecule designed by the company and licensed to Bristol Myers Squibb (BMS). EXS4318, a potentially first-in-class selective Protein kinase C (PKC) theta inhibitor, is the first clinical…

Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb

Scholar Rock has gone longer without a permanent CEO than their last hire was in the position—by almost two months. | Jay Backstrom will take the helm of Scholar Rock in October, more than 14 months after the company's last permanent CEO hire departed. Backstrom previously held executives roles at Acceleron and Celgene, both of…

A U.S. federal court on Friday shot down Bristol Myers Squibb’s motion to dismiss an investor lawsuit connected to its $74 billion Celgene buyout. | A U.S. federal court on Friday shot down Bristol Myers Squibb’s motion to dismiss an investor lawsuit connected to its $74 billion Celgene buyout.

Jeremy Moeller/Getty Images Only a day after Bristol Myers Squibb signed a licensing deal with Agenus with an upside potential of $1.56 billion, BMS inked a collaboration agreement with Exscientia, an Artificial Intelligence (AI)-focused biopharma company, that could hit $1.2 billion. The collaboration will leverage AI to speed the discovery of drug candidates in several therapeutic areas, including oncology and immunology.…

NEW YORK (Reuters) - We are all familiar with the challenges of 2020, but we may still be underestimating how deep and wide they go. FILE PHOTO: Workers walk in the city of London, Britain, September 21, 2018. Picture taken September 21, 2018. REUTERS/Peter Nicholls/File Photo Seven in 10 employees say this has been the…

FILE PHOTO: A security personnel stands guard at the opening session of Baidu's annual AI developers conference Baidu Create 2019 in Beijing, China, July 3, 2019. REUTERS/Jason Lee (Reuters) - Chinese search engine giant Baidu Inc BIDU.O said on Monday it would acquire JOYY Inc's YY.O video-based entertainment live streaming business…

The stairway near the entrance of Chicago’s McCormick Place during the 2019 ASCO meeting One of a new class of drugs being developed for multiple myeloma has shown a high response rate in patients who have received already failed on the so-called “backbone” treatments used for the disease, according to data presented at the recent…

FILE PHOTO - Logo of Didi Chuxing is seen at its headquarters building in Beijing, China August 28, 2018. REUTERS/Jason Lee BEIJING (Reuters) - China ride-hailing giant Didi Chuxing said on Wednesday that it will start using artificial intelligence (AI) technologies to verify if drivers in its Latin American markets wear masks and disinfect cars…

FILE PHOTO: German Chancellor Angela Merkel shakes hands with Indian Prime Minister Narendra Modi during their meeting in Berlin, Germany April 20, 2018. REUTERS/Axel Schmidt NEW DELHI (Reuters) - Germany and India are likely to sign agreements including a partnership on the use of artificial intelligence in farming during a three-day visit to New Delhi…

JERUSALEM (Reuters) - Israeli high-tech firm Cortica has partnered with some leading players in the automotive industry to form an artificial intelligence venture for autonomous driving, the company said on Wednesday. Given the shift toward self-driving cars, many in the industry are looking to incorporate AI into their systems to better deal with road hazards…

Robert Hershberg, MD, PhD, Celgene executive vice president and head of business development On its way to being acquired by Bristol-Myers Squibb (BMS), Celgene has restructured its three-year-old alliance with Jounce Therapeutics by terminating their up-to-$2.6 billion collaboration to develop multiple cancer immunotherapies, with Celgene instead committing potentially $530 million-plus for global licensing rights to a…